Evaluation of frequency magnetic field, static field, and Temozolomide on viability, free radical production and gene expression (p53) in the human glioblastoma cell line (A172)

ABSTRACT

Thirteen million cancer deaths and 21.7 million new cancer cases are expected in the world by 2030. Glioblastoma is the most common primary malignant tumor of the central nervous system which is the most lethal type of primary brain tumor in adults with the survival time of 12–15 months after the initial diagnosis. Glioblastoma is the most common and most malignant type of brain tumor, and despite surgery, chemotherapy and radiation treatment, the average survival of patients is about 14 months. The current research showed that the frequency magnetic field (FMF) and static magnetic field (SMF) can influence cancer cell proliferation and coupled with anticancer drugs may provide a new strategy for cancer therapy. At the present study, we investigated the effects of FMF (10 Hz, 50 G), SMF (50 G) and Temozolomide (200 μm) on viability, free radical production, and p53 followed by p53 protein expression in the human glioblastoma cell line (A172) by MTT, NBT, RT-PCR and Western blot. Results showed that the effect of Temozolomide (TMZ) with SMF and FMF together increased the cytotoxicity, free radical production, and p53 followed by p53 protein expression in the human glioblastoma cell line (A172).

KEYWORDS:

• Glioblastoma multiforme (GBM)
• human glioblastoma cell (A172)
• temozolomide (TMZ)
• frequency magnetic field (FMF)
• static magnetic field (SMF)
• p53 Apoptosis

Acknowledgments

This study has been financed by the Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.

Disclosure statement

The authors have declared that no conflict of interest exists.

Additional information

Funding

This work was supported by the Neuroscience Research Center, Kerman University of Medical Science, Kerman, Iran.